Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Forum Financial Management LP

Forum Financial Management LP increased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 47.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,884 shares of the biopharmaceutical company's stock after acquiring an additional 5,462 shares during the quarter. Forum Financial Management LP's holdings in Bristol-Myers Squibb were worth $955,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Pinney & Scofield Inc. purchased a new stake in Bristol-Myers Squibb in the 4th quarter worth $25,000. Fairway Wealth LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $28,000. Transce3nd LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $28,000. Comprehensive Financial Planning Inc. PA acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $34,000. Finally, Tacita Capital Inc acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Trading Up 0.2%

NYSE:BMY traded up $0.09 on Wednesday, reaching $46.98. 12,420,520 shares of the company's stock were exchanged, compared to its average volume of 13,140,393. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $95.61 billion, a price-to-earnings ratio of -10.63, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The business has a fifty day moving average of $51.26 and a 200-day moving average of $55.60. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.40) earnings per share. As a group, analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.28%. Bristol-Myers Squibb's payout ratio is 92.88%.

Insider Buying and Selling

In other news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction that occurred on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. UBS Group lowered their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research note on Friday, April 11th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 target price (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research report on Friday, February 7th. Finally, Jefferies Financial Group lowered their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.